Loading
A phase 3 trial of Gallium-68 gozetotide in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
PSMA PET Combined With MRI for the Detection of PCa is a phase 3 interventional study registered as NCT07052214 by Telix Pharmaceuticals (Innovations) Pty Limited, with 338 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-01. Interventions recorded: 68Ga-PSMA-11. Conditions listed: PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gallium-68 gozetotide (PSMA-11), Telix Pharmaceuticals, PSMA PET, Prostate cancer.
Shares Telix Pharmaceuticals, Prostate cancer.
Shares Gallium-68 gozetotide (PSMA-11), PSMA PET, Prostate cancer.
Shares Gallium-68 gozetotide (PSMA-11), PSMA PET, Prostate cancer.
Shares Gallium-68 gozetotide (PSMA-11), PSMA PET, Prostate cancer.
Shares PSMA PET, Prostate cancer.
Shares PSMA PET, Prostate cancer.
Shares PSMA PET, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/